203 related articles for article (PubMed ID: 34464969)
1. Nf1 and Sh2b3 mutations cooperate in vivo in a mouse model of juvenile myelomonocytic leukemia.
Morales CE; Stieglitz E; Kogan SC; Loh ML; Braun BS
Blood Adv; 2021 Sep; 5(18):3587-3591. PubMed ID: 34464969
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy in juvenile myelomonocytic leukemia: Where are we now?
De Vos N; Hofmans M; Lammens T; De Wilde B; Van Roy N; De Moerloose B
Pediatr Blood Cancer; 2022 Nov; 69(11):e29930. PubMed ID: 36094370
[TBL] [Abstract][Full Text] [Related]
3. [Juvenile myelomonocytic leukemia (JMML): recent advances in molecular pathogenesis and treatment].
Sakashita K
Rinsho Ketsueki; 2016 Feb; 57(2):137-46. PubMed ID: 26935631
[TBL] [Abstract][Full Text] [Related]
4. Juvenile myelomonocytic leukemia: who's the driver at the wheel?
Niemeyer CM; Flotho C
Blood; 2019 Mar; 133(10):1060-1070. PubMed ID: 30670449
[TBL] [Abstract][Full Text] [Related]
5. Current management of juvenile myelomonocytic leukemia and the impact of RAS mutations.
Yoshida N; Doisaki S; Kojima S
Paediatr Drugs; 2012 Jun; 14(3):157-63. PubMed ID: 22480363
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia.
Koike K; Matsuda K
Br J Haematol; 2008 May; 141(5):567-75. PubMed ID: 18422786
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis and treatment of juvenile myelomonocytic leukemia.
Sakashita K; Matsuda K; Koike K
Pediatr Int; 2016 Aug; 58(8):681-90. PubMed ID: 27322988
[TBL] [Abstract][Full Text] [Related]
8. RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia.
Lipka DB; Witte T; Toth R; Yang J; Wiesenfarth M; Nöllke P; Fischer A; Brocks D; Gu Z; Park J; Strahm B; Wlodarski M; Yoshimi A; Claus R; Lübbert M; Busch H; Boerries M; Hartmann M; Schönung M; Kilik U; Langstein J; Wierzbinska JA; Pabst C; Garg S; Catalá A; De Moerloose B; Dworzak M; Hasle H; Locatelli F; Masetti R; Schmugge M; Smith O; Stary J; Ussowicz M; van den Heuvel-Eibrink MM; Assenov Y; Schlesner M; Niemeyer C; Flotho C; Plass C
Nat Commun; 2017 Dec; 8(1):2126. PubMed ID: 29259247
[TBL] [Abstract][Full Text] [Related]
9. LNK/
Wintering A; Hecht A; Meyer J; Wong EB; Hübner J; Abelson S; Feldman K; Kennedy VE; Peretz CAC; French DL; Maguire JA; Jobaliya C; Vasquez MR; Desai S; Dulman R; Nemecek E; Haines H; Hammad M; El Haddad A; Kogan SC; Abdullaev Z; Chehab FF; Tasian SK; Smith CC; Loh ML; Stieglitz E
Haematologica; 2023 Dec; ():. PubMed ID: 38152053
[TBL] [Abstract][Full Text] [Related]
10. Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network.
Caye A; Strullu M; Guidez F; Cassinat B; Gazal S; Fenneteau O; Lainey E; Nouri K; Nakhaei-Rad S; Dvorsky R; Lachenaud J; Pereira S; Vivent J; Verger E; Vidaud D; Galambrun C; Picard C; Petit A; Contet A; Poirée M; Sirvent N; Méchinaud F; Adjaoud D; Paillard C; Nelken B; Reguerre Y; Bertrand Y; Häussinger D; Dalle JH; Ahmadian MR; Baruchel A; Chomienne C; Cavé H
Nat Genet; 2015 Nov; 47(11):1334-40. PubMed ID: 26457648
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of Gene Mutation and Clinical Characteristics in 19 Children with Juvenile Myelomonocytic Leukemia].
Weng KZ; Zheng YZ; Zhuang SQ; Chen HY; LE SH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1811-1818. PubMed ID: 33283703
[TBL] [Abstract][Full Text] [Related]
12. Juvenile myelomonocytic leukemia - A bona fide RASopathy syndrome.
Lasho T; Patnaik MM
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101171. PubMed ID: 32460983
[TBL] [Abstract][Full Text] [Related]
13. How I treat juvenile myelomonocytic leukemia.
Locatelli F; Niemeyer CM
Blood; 2015 Feb; 125(7):1083-90. PubMed ID: 25564399
[TBL] [Abstract][Full Text] [Related]
14. Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia.
Yoshida N; Yagasaki H; Xu Y; Matsuda K; Yoshimi A; Takahashi Y; Hama A; Nishio N; Muramatsu H; Watanabe N; Matsumoto K; Kato K; Ueyama J; Inada H; Goto H; Yabe M; Kudo K; Mimaya J; Kikuchi A; Manabe A; Koike K; Kojima S
Pediatr Res; 2009 Mar; 65(3):334-40. PubMed ID: 19047918
[TBL] [Abstract][Full Text] [Related]
15. Germline Neurofibromin 1 mutation enhances the anti-tumour immune response and decreases juvenile myelomonocytic leukaemia tumourigenicity.
Wang W; Li X; Qin X; Miao Y; Zhang Y; Li S; Yao R; Yang Y; Yu L; Zhu H; Song L; Mao S; Wang X; Chen J; Feng H; Li Y
Br J Haematol; 2023 Jul; 202(2):328-343. PubMed ID: 37144690
[TBL] [Abstract][Full Text] [Related]
16. JMML genomics and decisions.
Niemeyer CM
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):307-312. PubMed ID: 30504325
[TBL] [Abstract][Full Text] [Related]
17. Juvenile myelomonocytic leukemia.
Proytcheva M
Semin Diagn Pathol; 2011 Nov; 28(4):298-303. PubMed ID: 22195407
[TBL] [Abstract][Full Text] [Related]
18. RAS Pathway Mutation Patterns in Patients With Juvenile Myelomonocytic Leukemia: A Developing Country Single-center Experience.
Hamdy N; Bokhary H; Elsayed A; Hozayn W; Soliman S; Salem S; Alsheshtawi K; Abdalla A; Hafez H; Hammad M
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e368-e374. PubMed ID: 32209330
[TBL] [Abstract][Full Text] [Related]
19. [Juvenile myelomonocytic leukemias].
Lachenaud J; Strullu M; Baruchel A; Cavé H
Bull Cancer; 2014 Mar; 101(3):302-13. PubMed ID: 24691193
[TBL] [Abstract][Full Text] [Related]
20. Somatic mosaicism for oncogenic NRAS mutations in juvenile myelomonocytic leukemia.
Doisaki S; Muramatsu H; Shimada A; Takahashi Y; Mori-Ezaki M; Sato M; Kawaguchi H; Kinoshita A; Sotomatsu M; Hayashi Y; Furukawa-Hibi Y; Yamada K; Hoshino H; Kiyoi H; Yoshida N; Sakaguchi H; Narita A; Wang X; Ismael O; Xu Y; Nishio N; Tanaka M; Hama A; Koike K; Kojima S
Blood; 2012 Aug; 120(7):1485-8. PubMed ID: 22753870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
